Formulation and evaluation of lansoprazole oral disintegration tablets by moisture activated dry granulation (MADG) method

Abstract

In recent years, considerable attention has been focused on the development of novel drug delivery systems (NDDS).

The reason for this paradigm shift may be due to relatively low development cost and time required for introducing a

NDDS is low as compared to a new chemical entity. In the form of NDDS, an existing drug molecule can get a „new

life‟, thereby increasing its market value, competitiveness, and patent life. To fulfill these medical needs,

pharmaceutical technologists have developed a novel oral dosage form known as Orally Disintegrating Tablets

(ODTs) which disintegrate rapidly in saliva, usually in a matter of seconds, without the need to take water. Drug

dissolution and absorption as well as onset of clinical effect and drug bioavailability may be significantly greater than

those observed from conventional dosage forms. Therefore, in the present study an attempt will be made to formulate

Orodispersible tablets of Lansoprazole is a proton pump inhibitor which slow or prevent the production of acid within

the stomach. Lansoprazole is used to treat gastric (stomach) ulcers, duodenal (intestinal) ulcers, reflux esophagitis,

and gastro esophageal reflux disease (GERD)

The present study is planned with the following objectives:

 Preparation of Orodispersible tablets of Lansoprazole by Moisture activated dry granulation technique using

different concentration of superdisintegrates like sodium starch glycolate (Explotab) and crospovidone

(polyplasdone XL).

 Formulated Orodispersible tablets of Lansoprazole were evaluated for hardness, friability, weight variation,

disintegration time, wetting time and drug content estimation.

 In- vitro dissolution studies of Lansoprazole Orodispersible tablets.